In particular, the dual PI3K/PDK1 inhibitor NVP-BEZ235 is able to sensitize CML stem cells and progenitors to nilotinib, enhancing its cytotoxicity in TKi-resistant BCR-ABL mutant cells [114]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.